BoB@JPM: Ron Cooper, enGene

BoB@JPM: Ron Cooper, enGene

Author: Ben Comer January 26, 2026 Duration: 55:57

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/



Navigating the complex journey from a promising scientific idea to a commercially viable therapy involves far more than lab work. Business Of Biotech, hosted by Ben Comer, exists in that crucial space where scientific ambition meets real-world execution. This podcast speaks directly to the founders, executives, and visionaries steering emerging biopharma companies, offering a grounded conversation about the non-scientific hurdles that define success. You'll hear detailed discussions on the organizational, financial, and operational realities of the industry-from securing funding and building a team to managing clinical trials, manufacturing, and regulatory pathways. Each episode leans on the hard-earned wisdom of accomplished guests who share commentary and practical best practices. The focus is consistently on the multifaceted challenges leaders face while trying to bring a company from its earliest stages to impact in the clinic and the market. For anyone involved in building a life sciences company, this podcast provides an essential, candid look at the entire ecosystem, making the daunting path of biotech entrepreneurship feel a bit more navigable and a lot less lonely.
Author: Language: English Episodes: 100

Business Of Biotech
Podcast Episodes
Modernizing Clinical Trial Operations With Merck's Jennifer Sheller [not-audio_url] [/not-audio_url]

Duration: 55:39
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocol…
Engineering B Cells With Immusoft's Sean Ainsworth [not-audio_url] [/not-audio_url]

Duration: 53:51
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurshi…
Biotech Collaboration Strategy With IGI's Cyril Konto, M.D. [not-audio_url] [/not-audio_url]

Duration: 58:41
We love to hear from our listeners. Send us a message. On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antib…
Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D. [not-audio_url] [/not-audio_url]

Duration: 42:48
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May wit…
BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals [not-audio_url] [/not-audio_url]

Duration: 31:47
We love to hear from our listeners. Send us a message. On this week's episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Sc…